KEGG   DRUG: Rituximab
Entry
D02994                      Drug                                   

Name
Rituximab (USAN/INN);
Rituximab (genetical recombination) (JAN);
Rituximab (genetical recombination) [Rituximab biosimilar 1] (JAN);
Rituximab (genetical recombination) [Rituximab biosimilar 2] (JAN);
Rituximab-abbs;
Rituximab-pvvr;
Rituxan (TN);
Truximab (TN)
Product
Remark
Therapeutic category: 4291
ATC code: L01XC02
Product: D02994<JP/US>
Product (mixture): D11393<US>
Efficacy
Antineoplastic, Anti-CD20 antibody
  Disease
Non-Hodgkin's lymphoma (CD20-positive) [DS:H02418]
Chronic lymphocytic leukemia (CD20-positive) [DS:H00005]
Rheumatoid arthritis [DS:H00630]
Granulomatosis with polyangiitis; Wegener's granulomatosis [DS:H01655]
Microscopic polyangiitis [DS:H01658]
Pemphigus vulgaris [DS:H01648]
Comment
Monoclonal antibody
Target
CD20 [HSA:931] [KO:K06466]
  Pathway
hsa04640  Hematopoietic cell lineage
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC02 Rituximab
      D02994  Rituximab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Rituximab
    D02994  Rituximab (USAN/INN)
 Immunological Agents
  Immunosuppressants
   Immunosupressants, Other
    Rituximab
     D02994  Rituximab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D02994  Rituximab (USAN/INN); Rituximab (genetical recombination) (JAN); Rituximab (genetical recombination) [Rituximab biosimilar 1] (JAN); Rituximab (genetical recombination) [Rituximab biosimilar 2] (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD20
     D02994  Rituximab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D02994
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D02994
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D02994
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D02994
Other DBs
CAS: 174722-31-7
PubChem: 17397150
DrugBank: DB00073
NIKKAJI: J1.653.613J
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system